Recursion Pharmaceuticals

Recursion Pharmaceuticals Cash Flow per Share

The Operating Cash Flow per Share of Recursion Pharmaceuticals (RXRX) as of Oct 16, 2026 is -0.71 USD. In the previous year, Operating Cash Flow per Share was -1.07 USD — a change of -33.96% (higher).

Cash Flow per Share

-0.71USD

YoY

-33.96%

Last updated:

Operating Cash Flow per Share of Recursion Pharmaceuticals is 2025 -0.71 USD. Operating Cash Flow per Share of Recursion Pharmaceuticals was 2024 -1.07 USD. It decreases by -33.96% higher compared to the previous year.

The Recursion Pharmaceuticals Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
-2.59 USD
Jan 1, 2020
-0.27 USD
Jan 1, 2021
-0.94 USD
Jan 1, 2022
-0.45 USD
Jan 1, 2023
-1.23 USD
Jan 1, 2024
-1.07 USD
Jan 1, 2025
-0.71 USD
The Recursion Pharmaceuticals Cash Flow per Share history
YEARCash Flow per ShareYoY
-0.71USD-33.96%
-1.07USD-13.40%
-1.23USD+174.37%
-0.45USD-51.96%
-0.94USD+244.61%
-0.27USD-89.52%
-2.59USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals Inc is a biotechnology company based in Salt Lake City, Utah, operating in the Health Care sector. The company went public via an IPO on April 16, 2021. It employs approximately 600 people. Recursion Pharmaceuticals utilizes automation, artificial intelligence, and machine learning technologies to discover novel medicines. The company's platform, referred to as the Recursion Operating System (OS), integrates physical and digital components to map and navigate biological and chemical relationships. The company's approach involves iterative loops between wet lab biology and chemistry data, organized into cycles with computational tools to translate digital hypotheses into validated insights. Recursion Pharmaceuticals has clinical programs including REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is described as an orally bioavailable, superoxide scavenger small molecule being developed for the treatment of cerebral cavernous malformations. The company's website is www.recursion.com. It is listed under the ticker symbol RXRX with ISIN US75629V1044. The company's headquarters are located in Salt Lake City, Utah. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Operating Cash Flow per Share of Recursion Pharmaceuticals is -0.71 USD in 2025.

Operating Cash Flow per Share of Recursion Pharmaceuticals changed from -1.07 USD to -0.71 USD, representing a -33.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Recursion Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Recursion Pharmaceuticals